Short Interest in MDxHealth SA (NASDAQ:MDXH) Expands By 133.8%

MDxHealth SA (NASDAQ:MDXH) was the recipient of a significant increase in short interest in February. As of February 28th, there was short interest totalling 31,100 shares, an increase of 133.8% from the February 13th total of 13,300 shares. Based on an average daily trading volume, of 113,500 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.2% of the company’s shares are short sold.

MDxHealth Trading Down 1.3 %

MDxHealth stock traded down $0.02 during trading on Friday, reaching $1.48. 89,234 shares of the company were exchanged, compared to its average volume of 86,337. MDxHealth has a 52-week low of $1.35 and a 52-week high of $3.50. The company has a market capitalization of $69.99 million, a P/E ratio of -0.97 and a beta of 1.37. The company has a debt-to-equity ratio of 3.14, a current ratio of 1.54 and a quick ratio of 1.45. The stock’s 50 day simple moving average is $1.87 and its two-hundred day simple moving average is $2.10.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. MDxHealth had a negative return on equity of 1,077.84% and a negative net margin of 49.52%. The firm had revenue of $24.74 million for the quarter, compared to the consensus estimate of $22.67 million. On average, equities research analysts expect that MDxHealth will post -1.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MDxHealth

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC purchased a new stake in MDxHealth in the fourth quarter valued at $25,000. Oppenheimer & Co. Inc. raised its position in MDxHealth by 100.0% in the fourth quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company’s stock valued at $47,000 after purchasing an additional 10,000 shares during the period. FAS Wealth Partners Inc. raised its position in MDxHealth by 49.6% in the fourth quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company’s stock valued at $58,000 after purchasing an additional 8,100 shares during the period. XTX Topco Ltd purchased a new stake in MDxHealth in the fourth quarter valued at $63,000. Finally, Delta Investment Management LLC purchased a new stake in MDxHealth in the fourth quarter valued at $81,000.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.